Corvus Pharmaceuticals, Inc.
CRVS
$3.22
-$0.02-0.62%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -130.47% | -88.24% | 42.04% | 39.20% | 34.57% |
| Total Depreciation and Amortization | -43.71% | -57.14% | -63.70% | -65.28% | -58.86% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 487.90% | 261.25% | -77.93% | -61.36% | -47.72% |
| Change in Net Operating Assets | 54.17% | 90.48% | -41.94% | -41.36% | -354.53% |
| Cash from Operations | -6.22% | 15.92% | 23.63% | 26.92% | 11.43% |
| Capital Expenditure | -- | 100.00% | 100.00% | 100.00% | 87.36% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -276.49% | -269.55% | -805.95% | 52.24% | 167.63% |
| Cash from Investing | -276.85% | -269.70% | -331.57% | 58.43% | 166.77% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 346.38% | 109.48% | 122.61% | 196,175.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 524.16% | 287.27% | 308.31% | 196,175.00% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -619.85% | -244.08% | 134.50% | 89.92% | 98.93% |